IRVINE, Calif., July 30 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX) today announced that it has entered into an agreement to sell 3,900,000 shares of its common stock in an underwritten public offering at a price to the public of $4.10 per share. The gross proceeds to Endologix, before offering expenses, from the sale of shares are expected to be $15,990,000. The closing of the offering is expected to take place on August 4, 2009. Piper Jaffray & Co. will be the sole manager for the offering.
The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on May 8, 2009 that became effective on June 1, 2009. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. When available, copies of the prospectus supplement relating to the offering may be obtained upon request to Piper Jaffray & Co., at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by telephone at (800) 747-3924.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if
|SOURCE Endologix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved